Mocertatug rezetecan
Based on 1 Customer Validation
Mocertatug rezetecan (HS-20089; GSK5733584) is an antibody-drug conjugate (ADC) targeting B7-H4. Mocertatug rezetecan exhibits activity against platinum-resistant ovarian cancer. Mocertatug rezetecan is used for the research of advanced solid tumors, especially ovarian cancer and triple-negative breast cancer.
For research use only. We do not sell to patients.
- Purity: 97.29%
- CAS No.: 3042848-25-6
-
Storage:
-80°C, protect from light
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Biological Activity
-
Chemical Information
- Purity & Documentation
- References
-
Help & FAQs
Biological Activity
Chemical Information
-
CAS No. 3042848-25-6
-
Appearance Liquid
-
Color Colorless to light yellow
-
SMILES
[Mocertatug rezetecan]
-
Synonyms
HS-20089; GSK5733584
-
Shipping
Shipping with dry ice.
-
Storage
-80°C, protect from light
Purity & Documentation
-
Data Sheet (264 KB)
-
SDS (251 KB)
- English - EN (251 KB)
- Français - FR (251 KB)
- Deutsch - DE (251 KB)
- Norwegian - NO (251 KB)
- Español - ES (251 KB)
- Swedish - SV (251 KB)
- Italian - IT (251 KB)
- Korean - KR (251 KB)
- Portuguese - PT (251 KB)
-
Handling Instructions (2659 KB)
References
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Mocertatug rezetecan Related Classifications
HY-185280 Related Classifications
Powered by Bioz
- Mocertatug rezetecan
- 3042848-25-6
- HS-20089
- GSK5733584
- HS20089
- HS 20089
- GSK5733584
- GSK 5733584
- GSK-5733584
- Antibody-Drug Conjugates (ADCs)
- primary peritoneal cancer
- B7-H4
- ovarian cancer
- tumor cells
- primary peritoneal cancers
- triple-negative breast cancer
- fallopian tube cancers
- ovarian cancers
- platinum-resistant ovarian cancer
- fallopian tube cancer
- Inhibitor
- inhibitor
- inhibit